James D Griffin

James D Griffin

UNVERIFIED PROFILE

Are you James D Griffin?   Register this Author

Register author
James D Griffin

James D Griffin

Publications by authors named "James D Griffin"

Are you James D Griffin?   Register this Author

100Publications

2601Reads

23Profile Views

Notch1 activation enhances proliferation via activation of cdc2 and delays differentiation of myeloid progenitors.

Leuk Res 2018 09 30;72:34-44. Epub 2018 Jul 30.

Department of Pediatrics, School of Medicine, University of Yamanashi, 1110 Shimokato, Chuo, Yamamashi 409-3898, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2018.07.022DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6310156PMC
September 2018

Midostaurin, a Natural Product-Derived Kinase Inhibitor Recently Approved for the Treatment of Hematological Malignancies.

Biochemistry 2018 02 30;57(5):477-478. Epub 2017 Nov 30.

Department of Medical Oncology, Dana Farber Cancer Institute , Boston, Massachusetts 02215, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/acs.biochem.7b01126DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6295915PMC
February 2018

A Chemoproteomic Approach to Query the Degradable Kinome Using a Multi-kinase Degrader.

Cell Chem Biol 2018 01 9;25(1):88-99.e6. Epub 2017 Nov 9.

Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S24519456173038
Publisher Site
http://dx.doi.org/10.1016/j.chembiol.2017.10.005DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6427047PMC
January 2018

Structure-guided development of covalent TAK1 inhibitors.

Bioorg Med Chem 2017 02 9;25(3):838-846. Epub 2016 Dec 9.

Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02215, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bmc.2016.11.035DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5484537PMC
February 2017

Studies of TAK1-centered polypharmacology with novel covalent TAK1 inhibitors.

Bioorg Med Chem 2017 02 7;25(4):1320-1328. Epub 2016 Dec 7.

Department of Cancer Biology, Dana Farber Cancer Institute, Boston, MA 02115, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02215, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bmc.2016.11.034DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5484535PMC
February 2017

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice.

Authors:
Elizabeth C Townsend Mark A Murakami Alexandra Christodoulou Amanda L Christie Johannes Köster Tiffany A DeSouza Elizabeth A Morgan Scott P Kallgren Huiyun Liu Shuo-Chieh Wu Olivia Plana Joan Montero Kristen E Stevenson Prakash Rao Raga Vadhi Michael Andreeff Philippe Armand Karen K Ballen Patrizia Barzaghi-Rinaudo Sarah Cahill Rachael A Clark Vesselina G Cooke Matthew S Davids Daniel J DeAngelo David M Dorfman Hilary Eaton Benjamin L Ebert Julia Etchin Brant Firestone David C Fisher Arnold S Freedman Ilene A Galinsky Hui Gao Jacqueline S Garcia Francine Garnache-Ottou Timothy A Graubert Alejandro Gutierrez Ensar Halilovic Marian H Harris Zachary T Herbert Steven M Horwitz Giorgio Inghirami Andrew M Intlekofer Moriko Ito Shai Izraeli Eric D Jacobsen Caron A Jacobson Sébastien Jeay Irmela Jeremias Michelle A Kelliher Raphael Koch Marina Konopleva Nadja Kopp Steven M Kornblau Andrew L Kung Thomas S Kupper Nicole R LeBoeuf Ann S LaCasce Emma Lees Loretta S Li A Thomas Look Masato Murakami Markus Muschen Donna Neuberg Samuel Y Ng Oreofe O Odejide Stuart H Orkin Rachel R Paquette Andrew E Place Justine E Roderick Jeremy A Ryan Stephen E Sallan Brent Shoji Lewis B Silverman Robert J Soiffer David P Steensma Kimberly Stegmaier Richard M Stone Jerome Tamburini Aaron R Thorner Paul van Hummelen Martha Wadleigh Marion Wiesmann Andrew P Weng Jens U Wuerthner David A Williams Bruce M Wollison Andrew A Lane Anthony Letai Monica M Bertagnolli Jerome Ritz Myles Brown Henry Long Jon C Aster Margaret A Shipp James D Griffin David M Weinstock

Cancer Cell 2016 07 11;30(1):183. Epub 2016 Jul 11.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2016.06.008DOI Listing
July 2016

Discovery of a Highly Potent and Selective Indenoindolone Type 1 Pan-FLT3 Inhibitor.

ACS Med Chem Lett 2016 May 8;7(5):476-81. Epub 2016 Mar 8.

Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, United States; Department of Biological Chemistry & Molecular Pharmacology, Harvard Medical School, 360 Longwood Avenue, Longwood Center LC-2209, Boston, Massachusetts 02115, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/acsmedchemlett.5b00498DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4867484PMC
May 2016

Blood's 70th anniversary: arsenic--from poison pill to magic bullet.

Authors:
James D Griffin

Blood 2016 Apr;127(14):1729-30

Editor-in-Chief, Blood, 1993-1997.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2015-10-638650DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4825409PMC
April 2016

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice.

Authors:
Elizabeth C Townsend Mark A Murakami Alexandra Christodoulou Amanda L Christie Johannes Köster Tiffany A DeSouza Elizabeth A Morgan Scott P Kallgren Huiyun Liu Shuo-Chieh Wu Olivia Plana Joan Montero Kristen E Stevenson Prakash Rao Raga Vadhi Michael Andreeff Philippe Armand Karen K Ballen Patrizia Barzaghi-Rinaudo Sarah Cahill Rachael A Clark Vesselina G Cooke Matthew S Davids Daniel J DeAngelo David M Dorfman Hilary Eaton Benjamin L Ebert Julia Etchin Brant Firestone David C Fisher Arnold S Freedman Ilene A Galinsky Hui Gao Jacqueline S Garcia Francine Garnache-Ottou Timothy A Graubert Alejandro Gutierrez Ensar Halilovic Marian H Harris Zachary T Herbert Steven M Horwitz Giorgio Inghirami Andrew M Intlekofer Moriko Ito Shai Izraeli Eric D Jacobsen Caron A Jacobson Sébastien Jeay Irmela Jeremias Michelle A Kelliher Raphael Koch Marina Konopleva Nadja Kopp Steven M Kornblau Andrew L Kung Thomas S Kupper Nicole R LeBoeuf Ann S LaCasce Emma Lees Loretta S Li A Thomas Look Masato Murakami Markus Muschen Donna Neuberg Samuel Y Ng Oreofe O Odejide Stuart H Orkin Rachel R Paquette Andrew E Place Justine E Roderick Jeremy A Ryan Stephen E Sallan Brent Shoji Lewis B Silverman Robert J Soiffer David P Steensma Kimberly Stegmaier Richard M Stone Jerome Tamburini Aaron R Thorner Paul van Hummelen Martha Wadleigh Marion Wiesmann Andrew P Weng Jens U Wuerthner David A Williams Bruce M Wollison Andrew A Lane Anthony Letai Monica M Bertagnolli Jerome Ritz Myles Brown Henry Long Jon C Aster Margaret A Shipp James D Griffin David M Weinstock

Cancer Cell 2016 04;29(4):574-586

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, 450 Brookline Avenue, Dana 510B, MA 02215, USA; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2016.03.008DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5177991PMC
April 2016

Gene expression profiling analysis of CRTC1-MAML2 fusion oncogene-induced transcriptional program in human mucoepidermoid carcinoma cells.

BMC Cancer 2015 Oct 26;15:803. Epub 2015 Oct 26.

Deparment of Molecular Genetics and Microbiology, UF Health Cancer Center, University of Florida, Gainesville, FL, 32610, USA.

View Article

Download full-text PDF

Source
http://bmccancer.biomedcentral.com/articles/10.1186/s12885-0
Publisher Site
http://dx.doi.org/10.1186/s12885-015-1827-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4624166PMC
October 2015

Identification of ILK as a novel therapeutic target for acute and chronic myeloid leukemia.

Leuk Res 2015 Sep 9. Epub 2015 Sep 9.

Department of Radiation Oncology, Cancer Biology Division, Washington University in Saint Louis School of Medicine, St. Louis, MO, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2015.09.005DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5016250PMC
September 2015

Combination therapy with nilotinib for drug-sensitive and drug-resistant BCR-ABL-positive leukemia and other malignancies.

Arch Toxicol 2014 Dec 21;88(12):2233-42. Epub 2014 Oct 21.

Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00204-014-1385-5DOI Listing
December 2014

A genome-wide aberrant RNA splicing in patients with acute myeloid leukemia identifies novel potential disease markers and therapeutic targets.

Clin Cancer Res 2014 Mar 27;20(5):1135-45. Epub 2013 Nov 27.

Authors' Affiliations: Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts; Bioinformatics and Computational Genomics Laboratory, Institut de Recherches Cliniques de Montréal, Montreal, Quebec, Canada; Department of Computing Science, University of Alberta, Edmonton, Alberta, Canada; Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts; Dana-Farber Cancer Institute, Center for Cancer Systems Biology and Department of Genetics, Harvard Medical School, Boston University School of Medicine and Biomedical Engineering Department, Boston University, Boston, Massachusetts; Unité de Génomique du Myélome, Laboratoire UGM, University Hospital, CHU Rangueil, Toulouse, France; Hematology Laboratory, University Hospital; and INSERM U892, Nantes, France; Molecular Diagnostics Laboratory, Dana Farber Cancer Institute, Boston, Massachusetts; Biotique Systems Inc., www.biotiquesystems.com; Adult Leukemia Program, Dana Farber Cancer Institute, Boston, Massachusetts; Brigham and Women's Hospital, Boston, Massachusetts; Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-0956DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4458245PMC
March 2014

Discovery of a potent and selective DDR1 receptor tyrosine kinase inhibitor.

ACS Chem Biol 2013 Oct 13;8(10):2145-50. Epub 2013 Aug 13.

Cutaneous Biology Research Center, Massachusetts General Hospital and Harvard Medical School , Charlestown, Massachusetts 02129, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/cb400430tDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3800496PMC
October 2013

Structure of a pseudokinase-domain switch that controls oncogenic activation of Jak kinases.

Nat Struct Mol Biol 2013 Oct 8;20(10):1221-3. Epub 2013 Sep 8.

1] Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts, USA. [2] Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nsmb.2673DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3863620PMC
October 2013

Alternative splicing in chronic myeloid leukemia (CML): a novel therapeutic target?

Curr Cancer Drug Targets 2013 Sep;13(7):735-48

Dana-Farber cancer Institute, 450 Brookline ave, Boston, MA, USA 02215.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/15680096113139990083DOI Listing
September 2013

Discovery of a selective irreversible BMX inhibitor for prostate cancer.

ACS Chem Biol 2013 Jul 26;8(7):1423-8. Epub 2013 Apr 26.

High Magnetic Field laboratory, Chinese Academy of Sciences , P.O. Box 1110, Hefei, Anhui 230031, P. R. China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/cb4000629DOI Listing
July 2013

Development of 'DFG-out' inhibitors of gatekeeper mutant kinases.

Bioorg Med Chem Lett 2012 Aug 23;22(16):5297-302. Epub 2012 Jun 23.

Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bmcl.2012.06.036DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3415686PMC
August 2012

An amino-indazole scaffold with spectrum selective kinase inhibition of FLT3, PDGFRα and kit.

Bioorg Med Chem Lett 2012 Jul 6;22(14):4579-84. Epub 2012 Jun 6.

Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bmcl.2012.05.107DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3547541PMC
July 2012

Retrospective real-world comparison of medical visits, costs, and adherence between nilotinib and dasatinib in chronic myeloid leukemia.

Curr Med Res Opin 2010 Dec 9;26(12):2861-9. Epub 2010 Nov 9.

Analysis Group, Inc., Boston, Massachusetts, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1185/03007995.2010.533648DOI Listing
December 2010

Discovery and characterization of novel mutant FLT3 kinase inhibitors.

Mol Cancer Ther 2010 Sep 31;9(9):2468-77. Epub 2010 Aug 31.

Department of Medical Oncology/Hematologic Neoplasia, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-10-0232DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3967795PMC
September 2010

A robust error model for iTRAQ quantification reveals divergent signaling between oncogenic FLT3 mutants in acute myeloid leukemia.

Mol Cell Proteomics 2010 May 17;9(5):780-90. Epub 2009 Dec 17.

Department of Cancer Biology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1074/mcp.M900452-MCP200DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2871413PMC
May 2010

The mastermind-like 1 (MAML1) co-activator regulates constitutive NF-kappaB signaling and cell survival.

J Biol Chem 2010 May 15;285(19):14356-65. Epub 2010 Mar 15.

Department of Molecular Genetics and Microbiology, Shands Cancer Center, University of Florida, Gainesville, Florida 32610, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1074/jbc.M109.078865DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2863211PMC
May 2010

Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity.

Nat Med 2010 Apr 14;16(4):483-9. Epub 2010 Mar 14.

[1] Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA. [2] Department of Medical Oncology, Harvard Medical School, Boston, Massachusetts, USA. [3] Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nm.2112DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3786785PMC
April 2010

Wnt/β-catenin Pathway Modulates the Sensitivity of the Mutant FLT3 Receptor Kinase Inhibitors in a GSK-3β Dependent Manner.

Genes Cancer 2010 Feb;1(2):164-76

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1947601910362446DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3092187PMC
February 2010

JAK2 gets histone H3 rolling.

Cancer Cell 2009 Nov;16(5):365-6

Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccr.2009.10.009DOI Listing
November 2009

BCR-ABL promotes the frequency of mutagenic single-strand annealing DNA repair.

Blood 2009 Aug 1;114(9):1813-9. Epub 2009 Jul 1.

Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2008-07-172148DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2738569PMC
August 2009

FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML.

Drug Resist Updat 2009 Jun 20;12(3):81-9. Epub 2009 May 20.

Department of Medical Oncology/Hematologic Neoplasia, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.drup.2009.04.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4472331PMC
June 2009

Following the cytokine signaling pathway to leukemogenesis: a chronology.

J Clin Invest 2008 Nov;118(11):3564-73

Department of Medicine, Weill Medical College, Cornell University, New York, New York 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1172/JCI35819DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2575728PMC
November 2008

Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells.

Mol Cancer Ther 2008 May 29;7(5):1121-9. Epub 2008 Apr 29.

Department of Medical Oncology/Hematologic Neoplasia, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-07-2331DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4034541PMC
May 2008

The transcriptional coactivator Maml1 is required for Notch2-mediated marginal zone B-cell development.

Blood 2007 Nov 15;110(10):3618-23. Epub 2007 Aug 15.

Department of Medical Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://www.bloodjournal.org/cgi/doi/10.1182/blood-2007-06-09
Publisher Site
http://dx.doi.org/10.1182/blood-2007-06-097030DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2077311PMC
November 2007

Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study.

Blood 2007 Jun 15;109(11):5011-5. Epub 2007 Feb 15.

Department of Medical Oncology, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2006-01-015347DOI Listing
June 2007

Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia.

Nat Rev Cancer 2007 May;7(5):345-56

Dana Farber Cancer Institute, Mayer 540, 44 Binney Street, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/nrc2126
Publisher Site
http://dx.doi.org/10.1038/nrc2126DOI Listing
May 2007

PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR.

J Clin Invest 2007 Mar 8;117(3):730-8. Epub 2007 Feb 8.

Department of Physiology, National Laboratory of Medical Molecular Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1172/JCI28984DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1784000PMC
March 2007

Activated Jak2 with the V617F point mutation promotes G1/S phase transition.

J Biol Chem 2006 Jun 21;281(26):18177-83. Epub 2006 Apr 21.

Department of Medical Oncology, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1074/jbc.M600064200DOI Listing
June 2006

The Notch coactivator, MAML1, functions as a novel coactivator for MEF2C-mediated transcription and is required for normal myogenesis.

Genes Dev 2006 Mar 1;20(6):675-88. Epub 2006 Mar 1.

Department of Medical Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA.

View Article

Download full-text PDF

Source
http://www.genesdev.org/cgi/doi/10.1101/gad.1383706
Publisher Site
http://dx.doi.org/10.1101/gad.1383706DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1413284PMC
March 2006

Transforming activity of MECT1-MAML2 fusion oncoprotein is mediated by constitutive CREB activation.

EMBO J 2005 Jul 16;24(13):2391-402. Epub 2005 Jun 16.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/sj.emboj.7600719DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1173159PMC
July 2005

Interaction maps for kinase inhibitors.

Authors:
James D Griffin

Nat Biotechnol 2005 Mar;23(3):308-9

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nbt0305-308DOI Listing
March 2005

Activation of the PI3K/mTOR pathway by BCR-ABL contributes to increased production of reactive oxygen species.

Blood 2005 Feb 14;105(4):1717-23. Epub 2004 Oct 14.

Department of Medical Oncology, Dana-Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2004-03-0849DOI Listing
February 2005

After chronic myelogenous leukemia: tyrosine kinase inhibitors in other hematologic malignancies.

Blood 2005 Jan 9;105(1):22-30. Epub 2004 Sep 9.

Division of Hematologic Malignancy, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://www.bloodjournal.org/cgi/doi/10.1182/blood-2003-11-38
Publisher Site
http://dx.doi.org/10.1182/blood-2003-11-3896DOI Listing
January 2005

Patupilone (epothilone B) inhibits growth and survival of multiple myeloma cells in vitro and in vivo.

Blood 2005 Jan 14;105(1):350-7. Epub 2004 Sep 14.

Jerome Lipper Multiple Myeloma Center, Department of Adult Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2004-06-2499DOI Listing
January 2005

FLT3 tyrosine kinase as a target in acute leukemias.

Authors:
James D Griffin

Hematol J 2004 ;5 Suppl 3:S188-90

Dana Farber Cancer Institute, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/sj.thj.6200450DOI Listing
November 2004

Modulation of Notch signaling by mastermind-like (MAML) transcriptional co-activators and their involvement in tumorigenesis.

Semin Cancer Biol 2004 Oct;14(5):348-56

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.semcancer.2004.04.014DOI Listing
October 2004

Prediction of resistance to small molecule FLT3 inhibitors: implications for molecularly targeted therapy of acute leukemia.

Cancer Res 2004 Sep;64(18):6385-9

Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-04-2148DOI Listing
September 2004

Stable expression of small interfering RNA sensitizes TEL-PDGFbetaR to inhibition with imatinib or rapamycin.

J Clin Invest 2004 Jun;113(12):1784-91

Howard Hughes Medical Institute, Division of Hematology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1172/JCI20673DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC420507PMC
June 2004